IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Nanotechnology for Omics-Based Ocular Drug Delivery

Nanotechnology for Omics-Based Ocular Drug Delivery
View Sample PDF
Author(s): Anjali Hirani (University of South Florida, USA & Virginia Tech-Wake Forest University, USA), Aditya Grover (University of South Florida, USA), Yong Woo Lee (Virginia Tech-Wake Forest University, USA), Yashwant Pathak (University of South Florida, USA)and Vijaykumar Sutariya (University of South Florida, USA)
Copyright: 2017
Pages: 16
Source title: Oncology: Breakthroughs in Research and Practice
Source Author(s)/Editor(s): Information Resources Management Association (USA)
DOI: 10.4018/978-1-5225-0549-5.ch013

Purchase

View Nanotechnology for Omics-Based Ocular Drug Delivery on the publisher's website for pricing and purchasing information.

Abstract

Millions of people suffer from ocular diseases that impair vision and can lead to blindness. Advances in genomics and proteomics have revealed a number of different molecular markers specific for different ocular diseases, thereby optimizing the processes of drug development and discovery. Nanotechnology can increase the throughput of data obtained in omics-based studies and allows for more sensitive diagnostic techniques as more efficient drug delivery systems. Biocompatible and biodegradable nanomaterials developed through omics-based research are able to target reported molecular markers for different ocular diseases and offer novel alternatives to conventional drug therapy. In this chapter, the authors review the pathophysiology, current genomic and proteomic information, and current nanomaterial-based therapies of four ocular diseases: glaucoma, uveal melanoma, age-related macular degeneration, and diabetic retinopathy. Omics-based research can be used to elucidate specific genes and proteins and develop novel nanomedicine formulations to prevent, halt, or cure ocular diseases at the transcriptional or translational level.

Related Content

Genevieve Z. Steiner-Lim, Madilyn Coles, Kayla Jaye, Najwa-Joelle Metri, Ali S. Butt, Katerina Christofides, Jackson McPartland, Zainab Al-Modhefer, Diana Karamacoska, Ethan Russo, Tim Karl. © 2023. 47 pages.
Mohd Kashif, Mohammad Waseem, Poornima D. Vijendra, Ashok Kumar Pandurangan. © 2023. 28 pages.
Courtney R. Acker, Rana R. Zeine. © 2023. 27 pages.
Mahesh Pattabhiramaiah, Shanthala Mallikarjunaiah. © 2023. 16 pages.
Dhairavi Shah, Dhaara Shah, Yara Mohamed, Danna Rosas, Alyssa Moffitt, Theresa Hearn Haynes, Francis Cortes, Taunjah Bell Neasman, Phani kumar Kathari, Ana Villagran, Rana R. Zeine. © 2023. 28 pages.
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Aneesa Zafar, Shahid Bashir. © 2023. 23 pages.
Akila Muthuramalingam, Ashok Kumar Pandurangan, Subhamoy Banerjee. © 2023. 17 pages.
Body Bottom